Go Deep
StemCell Institute Inc.
StemCell Institute Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 23,877 | 48.6 | 2.65 | 0.19 | 433.44 |
| Oct 2026 | 23,885 | 48.2 | 2.65 | 0.19 | 432.01 |
StemCell Institute Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 722,002,000.0 | 667,329,000.0 | 728,921,000.0 | 714,106,000.0 |
| Net Profit | 35,988,000.0 | 9,345,000.0 | 61,681,000.0 | 41,786,000.0 |
| EPS | 3.6 | — | — | — |
StemCell Institute Inc. Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 2,811,344,000.0 | 2,679,175,000.0 | 2,481,193,000.0 | 2,091,293,000.0 | — |
| Net Profit | 155,917,000.0 | 385,796,000.0 | 310,981,000.0 | 198,032,000.0 | — |
| EPS | 15.4 | 37.7 | 30.4 | 19.3 | — |
StemCell Institute Inc. Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 8,124,841,000.0 | 7,500,939,000.0 | 6,543,075,000.0 | 5,811,615,000.0 | — |
| Total Liabilities | 5,442,797,000.0 | 4,873,091,000.0 | 3,850,462,000.0 | 3,513,027,000.0 | — |
| Total Equity | 2,682,044,000.0 | 2,627,848,000.0 | 2,692,613,000.0 | 2,298,588,000.0 | — |
Owes vs Owns
StemCell Institute Inc. owed ¥0.68 for every ¥1 it owned in Jun 2026, up from ¥0.60 in Mar 2023.
| Period | Jun 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.68× | 0.67× | 0.65× | 0.59× | 0.60× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
StemCell Institute Inc. Assets & Liabilities Breakdown (JPY millions)
What it owns — Mar 2026
Cash & short-term investments 34.9%Receivables 28.8%Inventory 0.7%Fixed assets (tangible) 16.9%Intangible assets 2.8%Long-term investments 10.2%Other assets 5.8%
How it's funded — Mar 2026
Short-term debt 0.8%Long-term debt 4.6%Payables 2.0%Other liabilities 59.6%Shareholders' equity 33.0%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 2,834.1 | 3,200.8 | 2,845.5 | 3,324.0 |
| Receivables | 2,337.0 | 1,840.7 | 1,588.3 | 1,140.8 |
| Inventory | 54.0 | 51.0 | 42.3 | 39.4 |
| Fixed assets (tangible) | 1,375.0 | 1,155.6 | 665.2 | 648.1 |
| Intangible assets | 225.6 | 132.4 | 41.6 | 24.5 |
| Long-term investments | 830.1 | 34.5 | 0.0 | 0.0 |
| Other assets | 468.9 | 1,086.0 | 1,360.2 | 634.8 |
| Liabilities & equity | ||||
| Short-term debt | 63.0 | 62.3 | 2.1 | 1.3 |
| Long-term debt | 377.1 | 437.6 | 6.7 | 4.6 |
| Payables | 161.0 | 24.9 | 35.3 | 30.2 |
| Other liabilities | 4,841.7 | 4,348.2 | 3,806.4 | 3,477.0 |
| Shareholders' equity | 2,682.0 | 2,627.8 | 2,692.6 | 2,298.6 |
| Net tangible assets | 2,456.4 | 2,495.5 | 2,651.0 | 2,274.1 |
StemCell Institute Inc. Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 73,509,000.0 | 467,685,000.0 | 334,625,000.0 | 99,672,000.0 | — |
| Investing Activities | -744,565,000.0 | -259,084,000.0 | -811,773,000.0 | -285,100,000.0 | — |
| Financing Activities | 231,558,000.0 | 146,704,000.0 | -1,333,000.0 | -869,000.0 | — |